159 related articles for article (PubMed ID: 18790752)
21. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
23. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine.
Videla-Richardson GA; Furmento VA; Garcia CP; Morris-Hanon O; Sevlever GE; Romorini L; Scassa ME
BMC Mol Cell Biol; 2019 Aug; 20(1):40. PubMed ID: 31462218
[TBL] [Abstract][Full Text] [Related]
24. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
25. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
28. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
30. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance.
Farahi N; Uller L; Juss JK; Langton AJ; Cowburn AS; Gibson A; Foster MR; Farrow SN; Marco-Casanova P; Sobolewski A; Condliffe AM; Chilvers ER
Clin Exp Allergy; 2011 May; 41(5):673-87. PubMed ID: 21255143
[TBL] [Abstract][Full Text] [Related]
31. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
32. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L; Deutsch E; Frascogna V; Chavaudra N; Jeanson L; Milliat F; Eschwege F; Bourhis J
Cancer Res; 2003 May; 63(10):2513-7. PubMed ID: 12750274
[TBL] [Abstract][Full Text] [Related]
34. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
35. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Molinsky J; Klanova M; Koc M; Beranova L; Andera L; Ludvikova Z; Bohmova M; Gasova Z; Strnad M; Ivanek R; Trneny M; Necas E; Zivny J; Klener P
Leuk Lymphoma; 2013 Feb; 54(2):372-80. PubMed ID: 22830613
[TBL] [Abstract][Full Text] [Related]
36. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
37. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
Bettayeb K; Baunbæk D; Delehouze C; Loaëc N; Hole AJ; Baumli S; Endicott JA; Douc-Rasy S; Bénard J; Oumata N; Galons H; Meijer L
Genes Cancer; 2010 Apr; 1(4):369-80. PubMed ID: 21779453
[TBL] [Abstract][Full Text] [Related]
38. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
Raynaud FI; Fischer PM; Nutley BP; Goddard PM; Lane DP; Workman P
Mol Cancer Ther; 2004 Mar; 3(3):353-62. PubMed ID: 15026556
[TBL] [Abstract][Full Text] [Related]
39. Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.
Houzé S; Hoang NT; Lozach O; Le Bras J; Meijer L; Galons H; Demange L
Molecules; 2014 Sep; 19(9):15237-57. PubMed ID: 25251193
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]